Genfit (Genfit) Retained Earnings : $-426.13 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Genfit Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Genfit's retained earnings for the quarter that ended in Dec. 2023 was $-426.13 Mil.

Genfit's quarterly retained earnings increased from Jun. 2023 ($-413.60 Mil) to Sep. 2023 ($0.00 Mil) but then declined from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($-426.13 Mil).

Genfit's annual retained earnings declined from Dec. 2021 ($-381.71 Mil) to Dec. 2022 ($-382.70 Mil) and declined from Dec. 2022 ($-382.70 Mil) to Dec. 2023 ($-426.13 Mil).

Genfit Retained Earnings Historical Data

The historical data trend for Genfit's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit Retained Earnings Chart

Genfit Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-337.20

-492.84

-381.71

-382.70

-426.13

Genfit Quarterly Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-	-382.70	-413.60	-	-426.13

Genfit Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Genfit (OTCPK:GNFTF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Genfit (Genfit) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (OTCPK:GNFTF) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

GNFT:USA 0QT6:UK GNFT:France XUPB:Germany

Address

Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120

Website

https://www.genfit.com

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.